title: Active treatment rates for lung cancer in south Manchester: are we doing enough?
abstract: In an effort to improve the current lung cancer treatment outcomes in Britain, National guidelines were published followed by the introduction of National Lung Cancer Audit (LUCADA) project. LUCADA has defined active treatment as any therapeutic intervention with the aim of improving the quality or length of patients' survival irrespective of whether it is curative or palliative. From August 2003 to December 2006, all patients diagnosed to be new primary lung cancer referrals were enrolled into a prospective study. Out of the total of 433 patients the majority of patients were male (62%) and the mean age was 69 years. The histologies were small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and other cancers in 67 (15.5%), 306 (70.7%) and 11 (2.5%) patients, respectively, while 49 (11.3%) patients had no histological confirmation. Overall, the active treatment rate was 72% with 74 (18%), 158 (36%), 66 (15%) and 11 (3%) undergoing surgery, chemotherapy, radiotherapy and other methods, respectively. The active treatment rates for histologically proven SCLC, NSCLC and all lung cancers excluding SCLC were 83%, 77% and 71%, respectively, compared to the LUCADA national average of 73.5%, 66% and 56.5%, respectively. Among the NSCLC patients overall five-year survival was 27.4%. The stage specific survivals were 64.0%, 58.3%, 24.1% and 11.5%, respectively, for stages I, II, III and IV. These reassuring results show that south Manchester has good active treatment rates for lung cancer with survival outcomes comparable to other major series.
authors.affiliation: Department of Cardiothoracic Surgery, University Hospital of South Manchester, Southmoor Road, Manchester M23 9LT, UK. mohandev@hotmail.com
authors.forename: Mohan P
authors.initials: MP
authors.lastname: Devbhandari
authors.forename: Vijay
authors.initials: V
authors.lastname: Joshi
authors.forename: Philip
authors.initials: P
authors.lastname: Barber
authors.forename: Piotr
authors.initials: P
authors.lastname: Krysiak
authors.forename: Rajesh
authors.initials: R
authors.lastname: Shah
authors.forename: Mark T
authors.initials: MT
authors.lastname: Jones
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D018288:Carcinoma, Small Cell / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D008297:Male; D008485:Medical Audit; D009367:Neoplasm Staging; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology